Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05360797
Other study ID # PADI_2
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 1, 2022
Est. completion date July 31, 2024

Study information

Verified date April 2022
Source Hospital Universitari Joan XXIII de Tarragona.
Contact Elena Ramírez-Maldonado, PhD
Phone 977295800
Email padibarcelona@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute pancreatitis (AP) is one of the most common reason for hospitalization among gastrointestinal diseases in U.S.. The costs caused by severe AP are higher than mild AP. Nevertheless, approximately 70% of hospital admissions for AP are mild cases, if health cost saving is to be realized, it would be by lowering the cost of managing patients with mild AP without affecting patient's safety and satisfaction. With the PADI-1 study, where it was possible to confirm the benefits of an early diet, the rapid recovery of patients with mild AP and the reduction of hospital costs, now a new scope is to be given in the treatment of patients with this pathology. Considering the application of predictive factors of AP severity, and being sure of diagnosing mild AP, a study of home care versus hospitalization for patients with mild AP is proposed. Based on the hypothesis that outpatient care of mild AP patients would be as sage and affective as hospitalization, the aim this study is to campare the results of 3 different strategies of treatment of patients with AP mild. Additionally, satisfaction patient and costs will be analyzed.


Description:

This is prospective, randomized, controlled, multicentre trial. OBJECTIVES Primary objective Compare the results of 3 different strategies for the management of patients with mild acute pancreatitis (AP) and to analyze differences in satisfaction patients and economic costs. METHODS Patients with mild AP will be randomly in three groups: group A: outpatient treatment, group B: medical home care and group C: hospitalization. The primary and several secondary endpoints will be obtained: 1. Treatment failure rate (the primary endpoint). 2. Serum amylase, lipase, electrolytes, BUN (blood urea nitrogen), creatinine, liver function tests, and full blood count at hospital admission, 24 hours and 72 hours. 3. Relapse pain. 4. Diet intolerance. 5. Systemic complications including hemodynamic instability, renal failure, intensive care admission, surgery, radiological and endoscopic procedures. 6. Pain and Analgesic requirement. 7. Local complications including pancreatic necrosis, abscess, pseudocyst. 8. Health costs 9. Patient satisfaction


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 225
Est. completion date July 31, 2024
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Diagnosed of AP by at least two of these three criteria: compatible abdominal pain, amylase or lipase level superior in three-fold respective laboratory baseline levels, and suitable findings in imaging techniques (CT, ultrasound or MRI). 2. age > 18 years, sign consent form. Exclusion Criteria: 1. pregnant o breastfeeding women. 2. abdominal pain lasting >96 horas before admission. 3. the possibility of poor oral intake for reasons other than AP. 4. Pancreatic neoplasm, endoscopic retrograde cholangiopancreatography or trauma etiology, biliar obstruction. 5. Chronic pancreatitis. 6. ASA =3. 7. Randomization lesser the 24 hours after randomization.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Outpatient
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the study investigators in each center.
Medical home care
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is discharged and contacted daily for 4 consecutive days by the medical home care department in each center.
Hospitalization
After a 24-hour stay in the emergency department, the predictive factors of severity evaluation and the diagnosis of mild acute pancreatitis is confirmed, the patient is hospitalized with usual treatment (PADI_1) in each center.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Elena Ramírez-Maldonado Consorci Sanitari del Maresme, Hospital Clinic of Barcelona

References & Publications (7)

Greenberg JA, Hsu J, Bawazeer M, Marshall J, Friedrich JO, Nathens A, Coburn N, May GR, Pearsall E, McLeod RS. Clinical practice guideline: management of acute pancreatitis. Can J Surg. 2016 Apr;59(2):128-40. Review. — View Citation

Ince AT, Senturk H, Singh VK, Yildiz K, Danalioglu A, Cinar A, Uysal O, Kocaman O, Baysal B, Gürakar A. A randomized controlled trial of home monitoring versus hospitalization for mild non-alcoholic acute interstitial pancreatitis: a pilot study. Pancreat — View Citation

Pando E, Alberti P, Mata R, Gomez MJ, Vidal L, Cirera A, Dopazo C, Blanco L, Gomez C, Caralt M, Balsells J, Charco R. Early Changes in Blood Urea Nitrogen (BUN) Can Predict Mortality in Acute Pancreatitis: Comparative Study between BISAP Score, APACHE-II, — View Citation

Ramírez-Maldonado E, López Gordo S, Pueyo EM, Sánchez-García A, Mayol S, González S, Elvira J, Memba R, Fondevila C, Jorba R. Immediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI — View Citation

Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30. — View Citation

Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi: 10.1016/j.pan.2013.07.063. — View Citation

Yokoe M, Takada T, Mayumi T, Yoshida M, Isaji S, Wada K, Itoi T, Sata N, Gabata T, Igarashi H, Kataoka K, Hirota M, Kadoya M, Kitamura N, Kimura Y, Kiriyama S, Shirai K, Hattori T, Takeda K, Takeyama Y, Hirota M, Sekimoto M, Shikata S, Arata S, Hirata K. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The treatment failure rate Treatment failure is defined as persistence, increase or recurrence of abdominal pain, and or intolerance diet, hospital admission, and mortality 30 days
Secondary Relapse of abdominal pain Pain Scale: 0=No pain, 1=Very mild, 2=Discomforting, 3=Tolerable, 4=Distressing, 5=Distressing, 6=Intense pain, 7=Very intense pain, 8=Horrible pain, 9=Excruciating, 10=Unimaginable pain 30 days
Secondary Diet tolerance Patient can eat at least 50% of the meals 30 days
Secondary Systemic Inflammatory Response Syndrome (SIRS) Score SIRS is a simple clinical score, ranging from 0-4, that utilizes objective, routine clinical parameters (body temperature, heart rate, respiratory rate or arterial carbon dioxide tension and white blood count) that directly reflect the underlying inflammatory response. A lower change in SIRS score (negative number) indicates a better outcome (less inflammation). 4 days
Secondary Number of Participants who Development of Organ Failure Including respiratory, renal and cardiovascular failures defined as modified Marshal score of equal and greater than 2. The minimum and maximum values in the modified Marshal score for each organ failure range from 0 to 4 with a higher value representing worse outcomes. 4 days
Secondary Mortality Enrolled subjects that died. A death indicates a worse outcome. 30 days
Secondary Hospital admission The AP patient needs hospital admission due to treatment failure 30 days
Secondary Satisfaction medical / hospital care patient satisfaction is asessed comparing management with and without admittance to the hospital. Will be assessed Patient satisfaction feedback (PSF). Scale: Strongly agree, Agree, Not sure, Disagree, Strongly disagree. 30 days
Secondary Health costs The costs in euros caused by diagnosis, treatment, stay in the emergency room, complications and follow-up 30 days
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Recruiting NCT04195347 - Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Phase 1/Phase 2
Completed NCT04735055 - Artificial Intelligence Prediction for the Severity of Acute Pancreatitis
Completed NCT02928718 - The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations
Terminated NCT02885441 - Treatment of Acute Pancreatitis With Ketorolac Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Recruiting NCT01626911 - Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis N/A
Completed NCT01507766 - The Correlations Between Early Enteral Nutrition and Intra-abdominal Pressure in Severe Acute Pancreatitis Phase 4
Completed NCT04901949 - The Course of Acute Pancreatitis in Patients With Different BMI Groups
Recruiting NCT04814693 - Conventional Endoscopic Techniques Versus EndoRotor® System for Necrosectomy of Walled of Necrosis N/A
Completed NCT02743364 - Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis Phase 2
Recruiting NCT05281458 - Early Versus Standard Endoscopic Interventions for Peripancreatic Fluid Collections N/A
Not yet recruiting NCT04990336 - Dachaihu Decoction Compound and Rhubarb Single Medicine in the Treatment of Acute Pancreatitis N/A
Not yet recruiting NCT03259880 - Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals N/A
Completed NCT02543658 - Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension Phase 2
Recruiting NCT06023771 - Invasive Intervention of Local Complications of Acute Pancreatitis
Not yet recruiting NCT05501314 - Remote Home Monitoring Acute Pancreatitis N/A
Completed NCT02897206 - Imipenem Prophylaxis in Patients With Acute Pancreatitis Phase 4
Recruiting NCT03634787 - Heat Shock Proteins: a Pathogenic Driver and Potential Therapeutic Target in Acute Pancreatitis
Active, not recruiting NCT04989166 - Effect of Nano-curcumin Supplementation in Acute Pancreatitis N/A